4.8 Article

Cocapture of cognate and bystander antigens can activate autoreactive B cells

出版社

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1614472114

关键词

tolerance; autoantibodies; antigen capture; antigen presentation; influenza

资金

  1. Swiss National Science Foundation Grants [310030_149966]
  2. MUAM award from the Medical Faculty of the University of Basel
  3. Swiss National Science Foundation (SNF) [310030_149966] Funding Source: Swiss National Science Foundation (SNF)

向作者/读者索取更多资源

Autoantibodies against myelin oligodendrocyte glycoprotein (MOG) are associated with autoimmune central nervous system diseases like acute disseminated encephalomyelitis (ADEM). For ADEM, it is speculated that a preceding infection is the trigger of the autoimmune response, but the mechanism connecting the infection to the production of MOG antibodies remains a mystery. We reasoned that the ability of B cells to capture cognate antigen from cell membranes, along with small quantities of coexpressed bystander antigens, might enable B-cell escape from tolerance. We tested this hypothesis using influenza hemagglutinin as a model viral antigen and transgenic, MOG-specific B cells. Using flow cytometry and live and fixed cell microscopy, we show that MOG-specific B cells take up large amounts of MOG from cell membranes. Uptake of the antigen from the membrane leads to a strong activation of the capturing B cell. When influenza hemagglutinin is also present in the membrane of the target cell, it can be cocaptured with MOG by MOG-specific B cells via the B-cell receptor. Hemagglutinin and MOG are both presented to T cells, which in turn are activated and proliferate. As a consequence, MOG-specific B cells get help from hemagglutinin-specific T cells to produce anti-MOG antibodies. In vivo, the transfer of MOG-specific B cells into recipient mice after the cocapture of MOG and hemagglutinin leads to the production of class-switched anti-MOG antibodies, dependent on the presence of hemagglutinin-specific T cells. This mechanism offers a link between infection and autoimmunity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

All Bruton's tyrosine kinase inhibitors have similar efficacy and risks: Commentary

Ozgur Yaldizli, Tobias Derfuss

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis

Alessandro Cagol, Sabine Schaedelin, Muhamed Barakovic, Pascal Benkert, Ramona-Alexandra Todea, Reza Rahmanzadeh, Riccardo Galbusera, Po-Jui Lu, Matthias Weigel, Lester Melie-Garcia, Esther Ruberte, Nina Siebenborn, Marco Battaglini, Ernst-Wilhelm Radue, Ozgur Yaldizli, Johanna Oechtering, Tim Sinnecker, Johannes Lorscheider, Bettina Fischer-Barnicol, Stefanie Mueller, Lutz Achtnichts, Jochen Vehoff, Giulio Disanto, Oliver Findling, Andrew Chan, Anke Salmen, Caroline Pot, Claire Bridel, Chiara Zecca, Tobias Derfuss, Johanna M. Lieb, Luca Remonda, Franca Wagner, Maria Vargas, Renaud Du Pasquier, Patrice H. Lalive, Emanuele Pravata, Johannes Weber, Philippe C. Cattin, Claudio Gobbi, David Leppert, Ludwig Kappos, Jens Kuhle, Cristina Granziera

Summary: Patients with relapsing multiple sclerosis (RMS) and disability progression independent of relapse activity (PIRA) exhibit accelerated brain atrophy, especially in the cerebral cortex.

JAMA NEUROLOGY (2022)

Article Clinical Neurology

Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder A Retrospective, Cross-sectional Analysis

Jannis Muller, Tim Sinnecker, Maria Janina Wendebourg, Regina Schlager, Jens Kuhle, Sabine Schadelin, Pascal Benkert, Tobias Derfuss, Philippe Cattin, Christoph Jud, Florian Spiess, Michael Amann, Therese Lincke, Muhamed Barakovic, Alessandro Cagol, Charidimos Tsagkas, Katrin Parmar, Anne-Katrin Probstel, Sophia Reimann, Susanna Asseyer, Ankelien Duchow, Alexander Brandt, Klemens Ruprecht, Nouchine Hadjikhani, Shoko Fukumoto, Mitsuru Watanabe, Katsuhisa Masaki, Takuya Matsushita, Noriko Isobe, Jun-Ichi Kira, Ludwig Kappos, Jens Wurfel, Cristina Granziera, Friedemann Paul, Ozgur Yaldizli

Summary: This study found that the choroid plexus volume was larger in patients with MS compared to those with NMOSD, healthy controls, and migraine patients. In contrast to NMOSD, the volume of the choroid plexus in MS was associated with the number of T2-weighted lesions.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)

Review Allergy

Normal B-cell ranges in infants: A systematic review and meta-analysis

Francesco Borriello, Noemi Pasquarelli, Lisa Law, Kim Rand, Catarina Raposo, Wei Wei, Licinio Craveiro, Tobias Derfuss

Summary: This study provides the first normal reference ranges for B-cell levels in infants, by week of age, during the first year of life.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients

Alexandra Ramona Todea, Lester Melie-Garcia, Muhamed Barakovic, Alessandro Cagol, Reza Rahmanzadeh, Riccardo Galbusera, Po-Jui Lu, Matthias Weigel, Esther Ruberte, Ernst-Wilhelm Radue, Sabine Schaedelin, Pascal Benkert, Yaldizli Oezguer, Tim Sinnecker, Stefanie Mueller, Lutz Achtnichts, Jochen Vehoff, Giulio Disanto, Oliver Findling, Andrew Chan, Anke Salmen, Caroline Pot, Patrice Lalive, Claire Bridel, Chiara Zecca, Tobias Derfuss, Luca Remonda, Franca Wagner, Maria Vargas, Renaud Du Pasquier, Emanuele Pravata, Johannes Weber, Claudio Gobbi, David Leppert, Jens Wuerfel, Tobias Kober, Benedicte Marechal, Ricardo Corredor-Jerez, Marios Psychogios, Johanna Lieb, Ludwig Kappos, Meritxell Bach Cuadra, Jens Kuhle, Cristina Granziera

Summary: This study evaluated the accuracy of LeMan-PV software for detecting new and enlarged white matter lesions in multiple sclerosis patients. The results showed that LeMan-PV had similar sensitivity in detecting new lesions compared to other recent studies using neural networks. Although its performance is not optimal, the main advantage of LeMan-PV is that it provides automated clinical decision support integrated into the routine radiological workflow.

JOURNAL OF MAGNETIC RESONANCE IMAGING (2023)

Editorial Material Clinical Neurology

Multiple sclerosis progression: time for a new mechanism-driven framework

Tanja Kuhlmann, Marcello Moccia, Timothy Coetzee, Jeffrey A. Cohen, Jorge Correale, Jennifer Graves, Ruth Ann Marrie, Xavier Montalban, V. Wee Yong, Alan J. Thompson, Daniel S. Reich

Summary: Traditionally, multiple sclerosis has been categorized into distinct clinical descriptors, but accumulating evidence suggests that it should be considered as a continuum with varying pathophysiological processes. A shift from acute injury to inflammation and neurodegeneration contributes to the progressive course, along with decreased neural resilience due to aging. Understanding the key mechanisms and quantifying progressive pathology can have implications for clinical care, treatment targets, and regulatory decisions.

LANCET NEUROLOGY (2023)

Editorial Material Clinical Neurology

Time to Change the Current Clinical Classification of Multiple Sclerosis?

Cristina Granziera, Tobias Derfuss, Ludwig Kappos

JAMA NEUROLOGY (2023)

Article Clinical Neurology

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

Stephanie Meier, Eline A. J. Willemse, Sabine Schaedelin, Johanna Oechtering, Johannes Lorscheider, Lester Melie-Garcia, Alessandro Cagol, Muhamed Barakovic, Riccardo Galbusera, Suvitha Subramaniam, Christian Barro, Ahmed Abdelhak, Simon Thebault, Lutz Achtnichts, Patrice Lalive, Stefanie Muller, Caroline Pot, Anke Salmen, Giulio Disanto, Chiara Zecca, Marcus D'Souza, Annette Orleth, Michael Khalil, Arabella Buchmann, Renaud Du Pasquier, Ozgur Yaldizli, Tobias Derfuss, Klaus Berger, Marco Hermesdorf, Heinz Wiendl, Fredrik Piehl, Marco Battaglini, Urs Fischer, Ludwig Kappos, Claudio Gobbi, Cristina Granziera, Claire Bridel, David Leppert, Aleksandra Maleska Maceski, Pascal Benkert, Jens Kuhle

Summary: This study found that serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) are correlated with features of disease progression in multiple sclerosis (MS) and can predict disease progression. sGFAP may serve as a useful biomarker for disease progression in MS in individual patient management and drug development.

JAMA NEUROLOGY (2023)

Article Clinical Neurology

Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets A MAGNIFY-MS Substudy

Heinz Wiendl, Klaus Schmierer, Suzanne Hodgkinson, Tobias Derfuss, Andrew Chan, Finn Sellebjerg, Anat Achiron, Xavier Montalban, Alexandre Prat, Nicola De Stefano, Frederik Barkhof, Letizia Leocani, Patrick Vermersch, Anita Chudecka, Claire Mwape, Kristina H. Holmberg, Ursula Boschert, Sanjeev Roy, MAGNIFY-MS Study Grp

Summary: Cladribine tablets cause a reduction in lymphocytes, with a predominant effect on B-cell and T-cell counts. The MAGNIFY-MS substudy reports the dynamic changes on multiple peripheral blood mononuclear cell (PBMC) subtypes and immunoglobulin (Ig) levels over 12 months after the first course of cladribine tablets in patients with highly active relapsing multiple sclerosis (MS).

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Article Clinical Neurology

Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis

Jannis Muller, Sabine Schadelin, Johannes Lorscheider, Pascal Benkert, Peter Hanni, Jurg Schmid, Jens Kuhle, Tobias Derfuss, Cristina Granziera, Ozgur Yaldizli

Summary: This study compared the effectiveness of dimethyl fumarate (DMF) and teriflunomide in a real-world setting and found that DMF treatment was associated with better clinical outcomes.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis

Nuria Cerda-Fuertes, Marc Stoessel, Gintaras Mickeliunas, Silvan Pless, Alessandro Cagol, Muhamed Barakovic, Aleksandra Maleska Maceski, Cesar alvarez Gonzalez, Marcus D' Souza, Sabine Schaedlin, Pascal Benkert, Pasquale Calabrese, Konstantin Gugleta, Tobias Derfuss, Till Sprenger, Cristina Granziera, Yvonne Naegelin, Ludwig Kappos, Jens Kuhle, Athina Papadopoulou

Summary: This study examined the relative role of optical coherence tomography (OCT) in multiple sclerosis (MS) and compared it with magnetic resonance imaging (MRI) and serum markers of disability. The results showed that OCT measures were associated with cognitive and physical disability, independent of serum and brain MRI markers of neuroaxonal loss.

MULTIPLE SCLEROSIS JOURNAL (2023)

Review Clinical Neurology

Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis A Systematic Review

Jannis Mueller, Alessandro Cagol, Johannes Lorscheider, Charidimos Tsagkas, Pascal Benkert, Ozgur Yaldizli, Jens Kuhle, Tobias Derfuss, Maria Pia Sormani, Alan Thompson, Cristina Granziera, Ludwig Kappos

Summary: Emerging evidence suggests that progression independent of relapse activity (PIRA) is a substantial contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (RRMS). To date, there is no uniform agreed-upon definition of PIRA, limiting the comparability of published studies.

JAMA NEUROLOGY (2023)

Article Clinical Neurology

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis

Ilaria Callegari, Mika Schneider, Vera Aebischer, Margarete M. M. Voortman, Undine Proschmann, Tjalf Ziemssen, Raija Lindberg, Bettina Fischer-Barnicol, Michael Khalil, Ludwig Kappos, Jens Kuhle, Nicholas S. R. Sanderson, Tobias Derfuss

Summary: This study found that natalizumab can diffuse in different anatomical compartments, including cerebrospinal fluid and milk. By developing a flow-cytometry-based assay and applying it to quantify natalizumab in body fluids, including cerebrospinal fluid, breastmilk, and serum, a better understanding of the safety of therapeutic antibody administration during pregnancy and lactation can be achieved.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2023)

Article Clinical Neurology

Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis

Nuria Cerda-Fuertes, Sara Nagy, Sabine Schaedelin, Tim Sinnecker, Esther Ruberte, Athina Papadopoulou, Jens Wurfel, Jens Kuhle, Ozgur Yaldizli, Ludwig Kappos, Tobias Derfuss, Bernhard F. Decard

Summary: This study aimed to describe the frequency, severity, and potential risk factors for recurring disease activity (RDA) in patients with multiple sclerosis (pwMS) after discontinuation of fingolimod (FGL). The results showed that younger age, shorter disease duration, and MRI activity during FGL treatment were independent risk factors for post-FGL RDA. Individual risk assessment and early switch to highly effective therapy can help minimize the risk of post-FGL RDA.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2023)

Article Clinical Neurology

Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination

Ana Beatriz Ayroza Galvao Ribeiro Gomes, Laila Kulsvehagen, Patrick Lipps, Alessandro Cagol, Nuria Cerda-Fuertes, Tradite Neziraj, Julia Flammer, Jasmine Lerner, Anne-Catherine Lecourt, Nina De Oliveira S. Siebenborn, Rosa Cortese, Sabine Schaedelin, Vinicius Andreoli Schoeps, Aline de Moura Brasil Matos, Natalia Trombini Mendes, Clarissa dos Reis Pereira, Mario Luiz Ribeiro Monteiro, Samira Luisa dos Apostolos-Pereira, Patrick Schindler, Claudia Chien, Carolin Schwake, Ruth Schneider, Thivya Pakeerathan, Orhan Aktas, Urs Fischer, Matthias Mehling, Tobias Derfuss, Ludwig Kappos, Ilya Ayzenberg, Marius Ringelstein, Friedemann Paul, Dagoberto Callegaro, Jens Kuhle, Athina Papadopoulou, Cristina Granziera, Anne-Katrin Probstel

Summary: This study investigated the frequency and clinical features of IgA antibodies against myelin oligodendrocyte glycoprotein (MOG) in patients with seronegative demyelinating central nervous system (CNS) disease. The results showed that MOG-specific IgA was identified in a subgroup of patients who were double-seronegative for aquaporin 4-/MOG-IgG, suggesting that MOG-IgA may be a novel diagnostic biomarker for patients with CNS demyelination.

JAMA NEUROLOGY (2023)

暂无数据